Nexus Medical Labs Expands Infectious Disease Testing with Scalable Oropouche Virus Assay

Nexus Medical Labs, a CLIA- and CAP-accredited diagnostic laboratory specializing in high-throughput molecular and immunoassay testing, has developed and validated an innovative diagnostic assay for the Oropouche virus. This new test supports early detection and rapid outbreak response and offers scalable diagnostics solutions for clinicians, healthcare providers, research institutions, and public health agencies.

The Oropouche virus, a vector-borne pathogen transmitted by biting midges and some mosquitoes, is responsible for disease outbreaks in tropical regions. With limited commercial diagnostic options available in the United States and the need for testing of travel-associated cases in the United States, Nexus Medical Labs' test fills a crucial gap by providing a highly sensitive molecular assay with rapid turnaround times. The assay has been validated for use in the United States.

"Oropouche presents a significant health risk, particularly to travelers, and addressing this challenge is essential for global health preparedness," said Evan Sullivan, CEO of Nexus Medical Labs. "We are proud to offer screening for this virus in coordination with Ginkgo Biosecurity with development funded in part by the U.S. Centers for Disease Control and Prevention to maintain a high state of readiness for any future public health threats. Our Oropouche assay ensures that healthcare providers and clinicians have a reliable and scalable testing partner in the event a future pandemic emerges.”

Addressing a Critical Gap in Infectious Disease Testing

The Oropouche virus has caused significant health risks in endemic regions and poses a potential threat to travelers due to a lack of available vaccines andclinical treatments. Nexus Medical Labs developed this assay in collaboration with Ginkgo Biosecurity and funded in part by the CDC to ensure the United States remains prepared for future public health threats.

"As part of our commitment to advancing infectious disease diagnostics, our team is proud to introduce the Oropouche assay," said Esther Brown, VP of Operations at Nexus Medical Labs. "This groundbreaking test offers rapid, accurate, and reliable detection of Oropouche virus, empowering clinicians with the information needed to make timely decisions. By integrating cutting-edge technology and rigorous validation protocols, we've ensured the assay meets the highest standards of reliability and sensitivity. This development is a significant step forward in managing infectious diseases and improving public health outcomes in areas where the Oropouche virus poses a critical threat."

Key Features of the Oropouche Virus Assay

✔ High Sensitivity & Specificity - Detects active infections using qPCR technology.

✔ Rapid Turnaround Time - Results available within 24-72 hours, enabling timely intervention.

✔ Scalable Processing Capacity - Automated lab systems capable of processing up to 85,000+ tests per month.

✔ Regulatory Compliance - CLIA- and CAP-accredited.

✔ Support for Public Health - Valuable for epidemiologists, healthcare providers, and government agencies managing infectious disease outbreaks.

Scaling Infectious Disease Diagnostics for the Future

The development of the Oropouche virus assay is part of Nexus Medical Labs' broader mission to support large-scale, automated diagnostic solutions. With expertise in molecular and immunoassays, Nexus enables healthcare companies, digital health brands, and research organizations to integrate high-quality diagnostics into their services seamlessly.

"Our ability to rapidly develop and deploy high-throughput diagnostic assays makes us a strategic partner for companies seeking reliable, scalable solutions," Sullivan added. "Nexus Medical Labs is positioned to provide early detection and rapid response for emerging infectious diseases to ensure healthcare providers and research institutions have access to fast, high-throughput diagnostic solutions.”

Nexus Medical Labs
313 Pleasant St
Watertown, MA 02472

For more information about the Oropouche virus diagnostic assay or to explore partnership opportunities, visit www.nexusmedlabs.com or contact:

Press Contact
Jill Sullivan
VP Growth
Jill@nexusmedlabs.com
(617) 322-5251

Founded during Harvard University's COVID-19 research efforts, Nexus Medical Labs is a leading diagnostic laboratory specializing in scalable molecular and immunoassay testing. With advanced automation, rapid turnaround times, and high-volume diagnostic capabilities, Nexus serves healthcare companies, digital health brands, research institutions, and public health organizations nationwide.

This release was published on openPR.